目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.4 YEARS CONSIDERED
1.4.1 CURRENCY CONSIDERED
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key secondary data sources
2.1.1.2 Key objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 MARKET ESTIMATION
2.2.1.1 Company revenue analysis (bottom-up approach)
2.2.1.2 MnM repository analysis & primary interviews
2.2.1.3 Insights from primary experts
2.2.1.4 Segmental market size estimation by top-down approach
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 STUDY ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
3.2 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
3.3 DISRUPTIVE TRENDS SHAPING ANTIBODY DISCOVERY SERVICES MARKET
3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

4 PREMIUM INSIGHTS
4.1 ANTIBODY DISCOVERY SERVICES MARKET OVERVIEW
4.2 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE AND COUNTRY (2024)
4.3 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2025 VS. 2030
4.4 ANTIBODY DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.5 ANTIBODY DISCOVERY SERVICES MARKET SHARE, BY TYPE
4.6 UNMET NEEDS & WHITE SPACES
4.7 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
4.9 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
4.10 VC/PRIVATE EQUITY INVESTMENT TRENDS
4.11 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
4.11.1 SUSTAINABILITY IMPACT
4.11.2 REGULATORY POLICIES & ACCESS INITIATIVES
4.12 IP/PATENT LANDSCAPE IN ANTIBODY DISCOVERY SERVICES MARKET

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Development of bispecific antibodies and antibody fragments
5.2.1.2 Rising number of antibody-drug conjugates in clinical trials
5.2.1.3 Increasing venture and partnership funding for biologics
5.2.2 RESTRAINTS
5.2.2.1 High costs and complexity of biologics discovery
5.2.2.2 Competition from alternative modalities
5.2.2.3 Patent cliffs for blockbuster monoclonal antibodies and rise of biosimilars
5.2.3 OPPORTUNITIES
5.2.3.1 End-to-end discovery-to-IND service bundles/one-stop shop models in antibody discovery
5.2.3.2 Integration of AI and automation in discovery workflow
5.2.4 CHALLENGES
5.2.4.1 Reagents and raw material supply chain bottlenecks
5.2.4.2 Fragmented data and disjointed workflow infrastructure

6 INDUSTRY TRENDS
6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
6.2 VALUE CHAIN ANALYSIS
6.3 ECOSYSTEM ANALYSIS
6.3.1 RAW MATERIAL SUPPLIERS
6.3.2 ANTIBODY DISCOVERY SERVICE PROVIDERS
6.3.3 END USERS
6.3.4 REGULATORY BODIES
6.4 INVESTMENT & FUNDING SCENARIO
6.4.1 MAJOR INVESTMENTS AND FUNDING
6.5 TECHNOLOGY ANALYSIS
6.5.1 KEY TECHNOLOGIES
6.5.1.1 Phage display platforms
6.5.1.2 Hybridoma technology
6.5.1.3 Single B-cell screening
6.5.2 COMPLEMENTARY TECHNOLOGIES
6.5.2.1 AI/ML-based protein structure prediction
6.5.2.2 Surface plasmon resonance (SPR)/Bio-layer interferometry (BLI)
6.5.2.3 Cryo-electron microscopy (CRYO-EM)
6.5.3 ADJACENT TECHNOLOGIES
6.5.3.1 CRISPR-based functional genomics
6.5.3.2 CHO cell line development
6.5.3.3 In-vivo modelling
6.6 PATENT ANALYSIS
6.6.1 METHODOLOGY
6.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2024
6.6.3 LIST OF KEY PATENTS
6.7 KEY CONFERENCES & EVENTS, 2025-2026
6.8 CASE STUDY ANALYSIS
6.8.1 BISPECIFIC ANTIBODY MANUFACTURABILITY ASSESSMENT AND OPTIMIZATION
6.8.2 ACCELERATING ANTIBODY DISCOVERY FOR PANDEMIC PREPAREDNESS
6.8.3 USE OF REPAB POLYCLONAL ANTIBODY SEQUENCING PLATFORM TO TO IDENTIFY PROTECTIVE ANTIBODIES FROM HUMAN HOSTS IMMUNE TO MALARIA
6.9 REGULATORY ANALYSIS
6.9.1 REGULATORY LANDSCAPE
6.9.1.1 North America
6.9.1.2 Europe
6.9.1.3 Asia Pacific
6.9.1.4 Rest of the World
6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.10 PORTER'S FIVE FORCES ANALYSIS
6.10.1 BARGAINING POWER OF SUPPLIERS
6.10.2 BARGAINING POWER OF BUYERS
6.10.3 THREAT OF NEW ENTRANTS
6.10.4 THREAT OF SUBSTITUTES
6.10.5 INTENSITY OF COMPETITIVE RIVALRY
6.11 KEY STAKEHOLDERS & BUYING CRITERIA
6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
6.11.2 KEY BUYING CRITERIA
6.12 IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET
6.12.1 INTRODUCTION
6.12.2 MARKET POTENTIAL OF AI

7 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE
7.1 INTRODUCTION
7.2 TARGET IDENTIFICATION & VALIDATION
7.2.1 INTEGRATION OF OMICS-DRIVEN INSIGHTS WITH HIGH-THROUGHPUT FUNCTIONAL VALIDATION TO PROPEL MARKET GROWTH
7.3 ANTIBODY ENGINEERING & OPTIMIZATION
7.3.1 ANTIBODY ENGINEERING & OPTIMIZATION, BY TECHNOLOGY
7.3.1.1 Phage display technology
7.3.1.1.1 Adoption of AI-enhanced phage display to augment segment growth
7.3.1.2 Hybridoma technology
7.3.1.2.1 Advancements in automation and single-cell integration to support segment growth
7.3.1.3 Single-cell technologies
7.3.1.3.1 Use of high-throughput, single-cell platforms to boost segment growth
7.3.1.4 Other antibody engineering & optimization technologies
7.4 ANTIGEN DESIGN & PRODUCTION
7.4.1 HIGH-QUALITY ANTIGEN DESIGN AND PRODUCTION TO SPUR SEGMENT GROWTH
7.5 IMMUNIZATION & HOST MANAGEMENT
7.5.1 RISING ADOPTION OF ADVANCED TRANSGENIC AND HUMANIZED MODELS TO PROPEL SEGMENT GROWTH
7.6 OTHER ANTIBODY DISCOVERY SERVICES

8 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST
8.1 INTRODUCTION
8.2 MOUSE & RAT
8.2.1 GROWING PRECLINICAL RESEARCH DEMAND TO DRIVE GROWTH
8.3 RABBIT
8.3.1 INCREASED RESEARCH AND DIAGNOSTIC APPLICATIONS TO FAVOR MARKET GROWTH
8.4 CHICKEN
8.4.1 INCREASING FOCUS OF THERAPEUTIC AND DIAGNOSTIC APPLICATIONS TO DRIVE MARKET
8.5 CAMELIDS
8.5.1 RISING ADOPTION OF NANOBODIES IN THERAPEUTICS AND DIAGNOSTICS TO BOOST MARKET GROWTH
8.6 OTHER HOSTS

9 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE
9.1 INTRODUCTION
9.2 MONOCLONAL ANTIBODIES
9.2.1 GROWING ADOPTION IN TISSUE TYPING FOR ORGAN & BLOOD TRANSPLANTS AND PERSONALIZED MEDICINES TO DRIVE MARKET
9.3 POLYCLONAL ANTIBODIES
9.3.1 DIVERSE EPITOPE RECOGNITION ABILITY OF POLYCLONAL ANTIBODIES TO SUPPORT SEGMENT GROWTH
9.4 OTHER MOLECULES

10 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 STRATEGIC COLLABORATIONS AND AI INTEGRATION TO BOLSTER GROWTH
10.3 ACADEMIC & RESEARCH INSTITUTES
10.3.1 INCREASING COLLABORATIVE RESEARCH AND RISING GRANT FUNDING TO AUGMENT MARKET GROWTH
10.4 OTHER END USERS

11 ANTIBODY DISCOVERY SERVICES MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 US to dominate antibody discovery services market during forecast period
11.2.3 CANADA
11.2.3.1 Innovative biotech community and strategic platform investments to propel market growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Transformative cross-border acquisitions and platform-driven antibody innovation to expedite market growth
11.3.3 UK
11.3.3.1 Ramped ADC innovation and surging biotech investment to propel market growth
11.3.4 FRANCE
11.3.4.1 Strategic biomanufacturing investments and AI-enabled innovation to support market expansion
11.3.5 ITALY
11.3.5.1 Advanced R&D infrastructure and biotech innovation to aid market growth
11.3.6 SPAIN
11.3.6.1 High biotech investment and innovation in advanced antibody modalities to drive market
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Scalable integrated platforms, strategic global certification, and domestic innovation acceleration to augment market growth
11.4.3 JAPAN
11.4.3.1 Enhanced translational platforms and strategic cross-border R&D partnerships to expedite market growth
11.4.4 INDIA
11.4.4.1 Advanced biomanufacturing platforms and innovation-led public-private partnerships to strengthen Indian market
11.4.5 SOUTH KOREA
11.4.5.1 AI platform investments and CDMO-led modality innovation to accelerate market growth
11.4.6 AUSTRALIA
11.4.6.1 High-throughput single-cell platforms and increased academic-industry collaborations to spur market growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Local biologics infrastructure expansion and collaborative innovation ecosystems to favor market growth
11.5.3 MEXICO
11.5.3.1 Focus on local emerging startups and industry-academic collaborations to aid antibody discovery services
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC COUNTRIES
11.6.2.1 UAE
11.6.2.1.1 High biomanufacturing investments and focus on global pharmaceutical partnerships to fuel market growth
11.6.2.2 Kingdom of Saudi Arabia
11.6.2.2.1 Advanced biologics infrastructure and strategic life science innovation hubs to bolster market growth
11.6.2.3 Rest of GCC Countries
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 ADVANCED REGIONAL MANUFACTURING CAPABILITIES AND BIOTECH INNOVATION ECOSYSTEMS TO DRIVE MARKET
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET
12.3 REVENUE ANALYSIS, 2020-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.5.5.1 Company footprint
12.5.5.2 Region footprint
12.5.5.3 Type footprint
12.5.5.4 Host footprint
12.5.5.5 Molecule footprint
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
12.6.5.1 List of key startups/SMEs
12.6.5.2 Competitive benchmarking of key startups/SMEs
12.7 COMPANY VALUATION & FINANCIAL METRICS
12.7.1 FINANCIAL METRICS
12.7.2 COMPANY VALUATION
12.8 BRAND/SERVICE COMPARISON
12.9 COMPETITIVE SCENARIO
12.9.1 SERVICE LAUNCHES
12.9.2 DEALS
12.9.3 EXPANSIONS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 WUXI BIOLOGICS
13.1.1.1 Business overview
13.1.1.2 Services offered
13.1.1.3 Recent developments
13.1.1.3.1 Deals
13.1.1.3.2 Expansions
13.1.1.4 MnM view
13.1.1.4.1 Right to win
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses & competitive threats
13.1.2 THERMO FISHER SCIENTIFIC INC.
13.1.2.1 Business overview
13.1.2.2 Services offered
13.1.2.3 Recent developments
13.1.2.3.1 Deals
13.1.2.3.2 Expansions
13.1.2.4 MnM view
13.1.2.4.1 Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses & competitive threats
13.1.3 CHARLES RIVER LABORATORIES
13.1.3.1 Business overview
13.1.3.2 Services offered
13.1.3.3 Recent developments
13.1.3.3.1 Deals
13.1.3.4 MnM view
13.1.3.4.1 Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses & competitive threats
13.1.4 EVOTEC
13.1.4.1 Business overview
13.1.4.2 Services offered
13.1.4.3 Recent developments
13.1.4.3.1 Deals
13.1.4.3.2 Contracts
13.1.4.3.3 Expansions
13.1.4.3.4 Other developments
13.1.4.4 MnM view
13.1.4.4.1 Right to win
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses & competitive threats
13.1.5 BIOCYTOGEN
13.1.5.1 Business overview
13.1.5.2 Services offered
13.1.5.3 Recent developments
13.1.5.3.1 Service launches
13.1.5.3.2 Deals
13.1.5.3.3 Expansions
13.1.5.4 MnM view
13.1.5.4.1 Right to win
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses & competitive threats
13.1.6 EUROFINS SCIENTIFIC
13.1.6.1 Business overview
13.1.6.2 Services offered
13.1.6.3 Recent developments
13.1.6.3.1 Expansions
13.1.7 SHANGHAI CHEMPARTNER
13.1.7.1 Business overview
13.1.7.2 Services offered
13.1.7.3 Recent developments
13.1.7.3.1 Deals
13.1.8 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY'S LABORATORIES)
13.1.8.1 Business overview
13.1.8.2 Services offered
13.1.8.3 Recent developments
13.1.8.3.1 Expansions
13.1.9 SINO BIOLOGICAL, INC.
13.1.9.1 Business overview
13.1.9.2 Services offered
13.1.9.3 Recent developments
13.1.9.3.1 Deals
13.1.9.3.2 Expansions
13.1.10 SAMSUNG BIOLOGICS
13.1.10.1 Business overview
13.1.10.2 Services offered
13.1.10.3 Recent developments
13.1.10.3.1 Service launches
13.1.11 GENSCRIPT
13.1.11.1 Business overview
13.1.11.2 Services offered
13.1.11.3 Recent developments
13.1.11.3.1 Service launches
13.1.11.3.2 Deals
13.1.12 CURIA GLOBAL, INC.
13.1.12.1 Business overview
13.1.12.2 Services offered
13.1.12.3 Recent developments
13.1.12.3.1 Deals
13.1.12.3.2 Other developments
13.1.13 TWIST BIOSCIENCE
13.1.13.1 Business overview
13.1.13.2 Services offered
13.1.13.3 Recent developments
13.1.13.3.1 Service launches
13.1.13.3.2 Deals
13.1.13.3.3 Expansions
13.1.14 HARBOUR BIOMED
13.1.14.1 Business overview
13.1.14.2 Services offered
13.1.14.3 Recent developments
13.1.14.3.1 Deals
13.1.14.3.2 Other developments
13.1.15 ARAGEN LIFE SCIENCES LTD.
13.1.15.1 Business overview
13.1.15.2 Services offered
13.1.15.3 Recent developments
13.1.15.3.1 Expansions
13.1.16 DANAHER CORPORATION
13.1.16.1 Business overview
13.1.16.2 Services offered
13.1.16.3 Recent developments
13.1.16.3.1 Deals
13.1.17 CREATIVE BIOLABS
13.1.17.1 Business overview
13.1.17.2 Services offered
13.1.18 VIVA BIOTECH
13.1.18.1 Business overview
13.1.18.2 Services offered
13.1.19 IMMUNOPRECISE ANTIBODIES LTD.
13.1.19.1 Business overview
13.1.19.2 Services offered
13.1.19.3 Recent developments
13.1.19.3.1 Deals
13.1.20 FUSION ANTIBODIES
13.1.20.1 Business overview
13.1.20.2 Services offered
13.2 OTHER PLAYERS
13.2.1 ABZENA
13.2.2 ALLOY THERAPEUTICS, INC.
13.2.3 INTEGRAL MOLECULAR
13.2.4 BIODURO
13.2.5 SYNBIO TECHNOLOGIES
13.2.6 ABSOLUTE ANTIBODY
13.2.7 ADIMAB
13.2.8 ISOGENICA
13.2.9 ABLEXIS
13.2.10 FAIRJOURNEY

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS